| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 83831-0119-01 | 83831-0119 | Cyclophosphamide | Frindovyx | 500.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Mar 19, 2025 | In Use | |
| 40051-0605-13 | 40051-0605 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 1, 2016 | In Use | |
| 21695-0382-08 | 21695-0382 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jul 19, 1978 | In Use | |
| 42737-0101-05 | 42737-0101 | temozolomide | TEMOZOLOMIDE | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec 31, 2018 | Jan 24, 2019 | In Use |
| 00469-0625-99 | 00469-0625 | enzalutamide | Xtandi | 40.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Aug 4, 2020 | In Use | |
| 23155-0688-41 | 23155-0688 | OCTREOTIDE ACETATE | OCTREOTIDE ACETATE | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Sep 3, 2019 | In Use | ||
| 00006-3026-04 | 00006-3026 | Pembrolizumab | Keytruda | 25.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Aug 1, 2019 | In Use | |
| 71335-2974-03 | 71335-2974 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 16, 2026 | In Use | |
| 43063-0426-40 | 43063-0426 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 28, 2013 | Aug 1, 2019 | In Use |
| 24658-0703-01 | 24658-0703 | ESTRADIOL | ESTRADIOL | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sep 10, 2021 | In Use | ||
| 54868-1119-03 | 54868-1119 | Prednisone | Prednisone | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct 5, 2004 | In Use | |
| 68727-0900-03 | 68727-0900 | asparaginase erwinia chrysanthemi (recombinant)-rywn | Rylaze | 20.0 mg/mL | Chemotherapy | Miscellaneous Agent | Enzyme | Intramuscular | Jun 30, 2021 | In Use | |
| 50090-1600-03 | 50090-1600 | ondansetron hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 5, 2015 | Aug 31, 2017 | In Use |
| 72485-0222-10 | 72485-0222 | GEMCITABINE HYDROCHLORIDE | Gemcitabine | 1.0 g/26.3mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan 15, 2020 | In Use | |
| 70771-1152-01 | 70771-1152 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec 5, 2017 | In Use | |
| 83831-0134-01 | 83831-0134 | Leuprolide acetate | LUTRATE DEPOT | 22.5 mg/2ml | Hormonal Therapy | GnRH Agonist | Intramuscular | Mar 26, 2025 | In Use | ||
| 49999-0153-21 | 49999-0153 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb 9, 2012 | In Use | |
| 50090-1704-00 | 50090-1704 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Feb 18, 2015 | In Use | ||
| 63323-0128-20 | 63323-0128 | Dacarbazine | Dacarbazine | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Purine Analog | Intravenous | Sep 7, 2001 | In Use | |
| 00078-0683-61 | 00078-0683 | Nelarabine | Arranon | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Aug 2, 2019 | Sep 30, 2026 | In Use |
| 68084-0149-11 | 68084-0149 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov 13, 2013 | In Use | |
| 60219-1716-02 | 60219-1716 | Lenalidomide | LENALIDOMIDE | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 12, 2025 | In Use | |
| 50436-4324-02 | 50436-4324 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 21, 1972 | In Use | |
| 63187-0526-06 | 63187-0526 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 1, 2019 | In Use | |
| 00781-3491-94 | 00781-3491 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Nov 1, 2024 | In Use |
Found 12482 results — Export these results
Home